Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series
<b>Background</b>: The current possible treatments of advanced medullary carcinoma (MTC) include different drugs belonging to the class of tyrosine kinase inhibitors (TKIs): vandetanib, cabozantinb, and selpercatinib. Although the effects of these TKIs have been well described in clinica...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/12/2923 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846105666530312192 |
|---|---|
| author | Marilda Mormando Rosa Lauretta Giulia Puliani Marta Bianchini Maria Elena Spoltore Marialuisa Appetecchia |
| author_facet | Marilda Mormando Rosa Lauretta Giulia Puliani Marta Bianchini Maria Elena Spoltore Marialuisa Appetecchia |
| author_sort | Marilda Mormando |
| collection | DOAJ |
| description | <b>Background</b>: The current possible treatments of advanced medullary carcinoma (MTC) include different drugs belonging to the class of tyrosine kinase inhibitors (TKIs): vandetanib, cabozantinb, and selpercatinib. Although the effects of these TKIs have been well described in clinical trials, the real-practice evidence of the effectiveness and safety of these treatment is scant. This real-world case series aims to describe a niche of patients with advanced MTC treated with more than one TKI by focusing on treatment responses and any reported adverse events (AEs) and to provide additional insight on the individualized approach to the management of metastatic MTC. <b>Methods</b>: Five patients with a diagnosis of metastastic MTC, treated with at least two different molecules of TKIs, were retrospectively selected. <b>Results</b>: Three patients obtained a partial response (one with cabozantinb, one with selpercatinib, and one with vandetanib), and two patients obtained disease stability (both of them treated with all three TKIs, the first two lines discontinued for AEs). The AE profile agreed with the known clinical trials AEs except for non-neoplastic ascites related to selpercatinib and lung cavitations of non-neoplastic tissue related to cabozantinb. The latter was an AE never described so far in patients receiving TKIs. <b>Conclusions</b>: The best management of MTC relies on an individualized approach, keeping in mind and dealing with the potential toxicity in order to minimize the treatment withdrawal. |
| format | Article |
| id | doaj-art-db8cdf43601c4c94b50c8f2c6cc3a38a |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-db8cdf43601c4c94b50c8f2c6cc3a38a2024-12-27T14:13:16ZengMDPI AGBiomedicines2227-90592024-12-011212292310.3390/biomedicines12122923Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case SeriesMarilda Mormando0Rosa Lauretta1Giulia Puliani2Marta Bianchini3Maria Elena Spoltore4Marialuisa Appetecchia5Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalySection of Medical Pathophysiology, Food Science and Endocrinology, Department of Experimental Medicine, Sapienza University of Roma, 00185 Rome, ItalyOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy<b>Background</b>: The current possible treatments of advanced medullary carcinoma (MTC) include different drugs belonging to the class of tyrosine kinase inhibitors (TKIs): vandetanib, cabozantinb, and selpercatinib. Although the effects of these TKIs have been well described in clinical trials, the real-practice evidence of the effectiveness and safety of these treatment is scant. This real-world case series aims to describe a niche of patients with advanced MTC treated with more than one TKI by focusing on treatment responses and any reported adverse events (AEs) and to provide additional insight on the individualized approach to the management of metastatic MTC. <b>Methods</b>: Five patients with a diagnosis of metastastic MTC, treated with at least two different molecules of TKIs, were retrospectively selected. <b>Results</b>: Three patients obtained a partial response (one with cabozantinb, one with selpercatinib, and one with vandetanib), and two patients obtained disease stability (both of them treated with all three TKIs, the first two lines discontinued for AEs). The AE profile agreed with the known clinical trials AEs except for non-neoplastic ascites related to selpercatinib and lung cavitations of non-neoplastic tissue related to cabozantinb. The latter was an AE never described so far in patients receiving TKIs. <b>Conclusions</b>: The best management of MTC relies on an individualized approach, keeping in mind and dealing with the potential toxicity in order to minimize the treatment withdrawal.https://www.mdpi.com/2227-9059/12/12/2923medullary thyroid cancercabozantinibvandetanibselpercatinibadverse eventslung cavitations |
| spellingShingle | Marilda Mormando Rosa Lauretta Giulia Puliani Marta Bianchini Maria Elena Spoltore Marialuisa Appetecchia Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series Biomedicines medullary thyroid cancer cabozantinib vandetanib selpercatinib adverse events lung cavitations |
| title | Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series |
| title_full | Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series |
| title_fullStr | Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series |
| title_full_unstemmed | Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series |
| title_short | Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series |
| title_sort | treatment outcomes and toxicities of multiple tyrosin kinase inhibitors for metastatic medullary thyroid cancer a case series |
| topic | medullary thyroid cancer cabozantinib vandetanib selpercatinib adverse events lung cavitations |
| url | https://www.mdpi.com/2227-9059/12/12/2923 |
| work_keys_str_mv | AT marildamormando treatmentoutcomesandtoxicitiesofmultipletyrosinkinaseinhibitorsformetastaticmedullarythyroidcanceracaseseries AT rosalauretta treatmentoutcomesandtoxicitiesofmultipletyrosinkinaseinhibitorsformetastaticmedullarythyroidcanceracaseseries AT giuliapuliani treatmentoutcomesandtoxicitiesofmultipletyrosinkinaseinhibitorsformetastaticmedullarythyroidcanceracaseseries AT martabianchini treatmentoutcomesandtoxicitiesofmultipletyrosinkinaseinhibitorsformetastaticmedullarythyroidcanceracaseseries AT mariaelenaspoltore treatmentoutcomesandtoxicitiesofmultipletyrosinkinaseinhibitorsformetastaticmedullarythyroidcanceracaseseries AT marialuisaappetecchia treatmentoutcomesandtoxicitiesofmultipletyrosinkinaseinhibitorsformetastaticmedullarythyroidcanceracaseseries |